We found that CDK4/6i alone reduced MCM3 levels in both endocrine-sensitive (MCF7/S0.5) and -resistant (TamR-1, LetR-1, and FulvR-1) breast cancer cell lines (Fig. 6a). Here, CDK4 is linked to breast carcinoma.